ロード中...
Glatiramer acetate treatment negatively regulates type I interferon signaling
OBJECTIVE: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-...
保存先:
| 出版年: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4645172/ https://ncbi.nlm.nih.gov/pubmed/26601118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000179 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|